Generation of αGal-enhanced bifunctional tumor vaccine

He, Jianlin; Huo, Yu; Zhang, Zhikun; Luo, Yiqun; Liu, Xiuli; Chen, Qiaoying; Wu, Pan; Shi, Wei; Wu, Tao; Tang, Chao; Wang, Huixue; Li, Lan; Liu, Xiyu; Huang, Yong; Zhao, Yongxiang; Gan, Lu; Wang, Bing; Zhong, Liping

doi:10.1016/j.apsb.2022.03.002

Cited by 4 publications

(2 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…3 E). Generally, ICD would recruit and activate DCs for antigen recognization and presentation 47 , 48 , 49 . Next, a transwell system was carried out to assess the DCs maturation behavior (Supporting Information Fig.…”

Section: Resultsmentioning

confidence: 99%

A metabolic intervention strategy to break evolutionary adaptability of tumor for reinforced immunotherapy

Feng

Hao²,

Yang³

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 99%

A metabolic intervention strategy to break evolutionary adaptability of tumor for reinforced immunotherapy

Feng

Hao²,

Yang³

et al. 2023

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

“…[1][2][3][4] Among the various tumor immunotherapies, tumor vaccines have unparalleled advantages that they not only can eliminate tumors directly, but also induce immune memory to prevent tumor metastasis and recurrence. [5][6][7][8][9] Free antigens are confronted with ineffective costimulatory factor activation, which leads to their poor immunogenicity. Therefore, adjuvants are often introduced in vaccine formulations to stimulate innate immune cells and induce T cell responses.…”

Section: Introductionmentioning

confidence: 99%

Vaccination of TLR7/8 Agonist‐Conjugated Antigen Nanoparticles for Cancer Immunotherapy

Wang

Zhang

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Nanovaccine‐based immunotherapy can initiate strong immune responses and establish a long‐term immune memory to prevent tumor invasion and recurrence. Herein, the assembly of redox‐responsive antigen nanoparticles (NPs) conjugated with imidazoquinoline‐based TLR7/8 agonists for lymph node‐targeted immune activation is reported, which can potentiate tumor therapy and prevention. Antigen NPs are assembled via the templating of zeolitic imidazolate framework‐8 NPs to cross‐link ovalbumin with disulfide bonds, which enables the NPs with redox‐responsiveness for improved antigen cross‐presentation and dendritic cell activation. The formulated nanovaccines promote the lymphatic co‐delivery of antigens and agonists, which can trigger immune responses of cytotoxic T lymphocytes and strong immunological memory. Notably, nanovaccines demonstrate their superiority for tumor prevention owing to the elicited robust antitumor immunity. The reported strategy provides a rational design of nanovaccines for enhanced cancer immunotherapy.

show abstract

Progress of Oncolytic Virus

Wu,

Zhao,

et al. 2024

j biomed nanotechnol

View full text Add to dashboard Cite

Oncolytic viruses have made tremendous advances in fundamental research and clinical trials in recent years as potential anti-cancer medications. Oncolytic viruses, which are either genetically modified or naturally occurring, can kill cancer cells without harming healthy cells. At present, surgical treatment, radiotherapy, chemotherapy, and targeted drug therapy are the current conventional tumor treatment methods, but the curative effect is still not good for most cancer patients, especially at advanced stages of cancer. With the rapid development of molecular biology, viral vectors that can activate the body’s immune system have become increasingly popular as a means of enhancing anti-tumor efficacy. Increasing numbers of natural viruses are being generated and manipulated to enhance their infectivity or immunological activity against tumor cells. An oncolytic virus is a biologically effective preparation that performs its function by entering the body via an intra-tumor injection, intravenous or intraspinal drip, and other routes. Oncolytic viruses has the potential to treat solid tumors as well as non-solid tumors. They can selectively replicate and proliferate in tumor cells, which activates the immune system against the tumor of the host and recruits more efficient lymphocytes in the tumor microenvironment, thereby killing tumor cells. Moreover, it shows broad clinical application prospects.

show abstract

Generation of αGal-enhanced bifunctional tumor vaccine

Cited by 4 publications

References 27 publications

A metabolic intervention strategy to break evolutionary adaptability of tumor for reinforced immunotherapy

A metabolic intervention strategy to break evolutionary adaptability of tumor for reinforced immunotherapy

Vaccination of TLR7/8 Agonist‐Conjugated Antigen Nanoparticles for Cancer Immunotherapy

Progress of Oncolytic Virus

Contact Info

Product

Resources

About